샘플 요청 목록

 카트 문의
시장보고서
상품코드
1655602

세계의 전립선암 치료제 시장

Prostate Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 212 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 전립선암 치료제 시장은 2030년까지 264억 달러에 달할 전망

2024년에 180억 달러로 추정되는 세계의 전립선암 치료제 시장은 분석 기간인 2024-2030년에 CAGR 6.6%로 성장하며, 2030년에는 264억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 호르몬 요법은 CAGR 6.8%를 기록하며, 분석 기간 종료시에는 210억 달러에 달할 것으로 예측됩니다. 표적치료 분야의 성장률은 분석 기간 중 CAGR 5.8%로 추정됩니다.

미국 시장은 50억 달러로 추정, 중국은 CAGR 6.0%로 성장 예측

미국의 전립선암 치료제 시장은 2024년에 50억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 40억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.0%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.2%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 5.1%로 성장할 것으로 예측됩니다.

세계의 전립선암 치료제 시장 - 주요 동향과 촉진요인 정리

전립선암에 대한 현재의 치료법은?

전립선암 치료제는 전립선암을 관리하고 치료하기 위해 고안된 다양한 치료법을 포함하고 있으며, 전립선암은 전 세계에서 가장 흔한 암 중 하나입니다. 주요 치료법으로는 수술, 방사선 치료, 호르몬 치료, 화학요법, 그리고 최근에는 면역 요법 및 표적 치료 등이 있습니다. 근치적 전립선 절제술과 같은 수술요법은 전립선을 제거하는 것으로 국한된 암에 권장되는 치료법입니다. 방사선 치료는 외부 방사선 조사 또는 방사선 요법을 통해 고에너지 선으로 암세포를 표적으로 삼는 치료법입니다. 호르몬 요법 또는 안드로겐 제거 요법(ADT)은 전립선암의 성장을 가속하는 남성 호르몬 수치를 낮춥니다. 화학요법은 초기에는 잘 사용되지 않지만, 진행성 전립선암이나 호르몬 저항성 전립선암에 사용됩니다. 이러한 치료는 효과를 극대화하고 보다 종합적으로 질병을 관리하기 위해 종종 병용하여 사용됩니다.

새로운 치료법은 전립선암 치료 환경을 어떻게 바꾸고 있는가?

새로운 치료법은 전립선암의 치료 환경을 혁신적으로 변화시키고 있으며, 보다 표적화된 맞춤형 치료 옵션을 제공합니다. 가장 유망한 분야 중 하나는 엔잘루타미드와 아파타미드와 같은 새로운 안드로겐 수용체 억제제의 개발로, 암의 증식을 촉진하는 신호를 차단하는 데 매우 효과적입니다. 면역요법, 특히 면역관문억제제의 사용도 전립선암에서 다른 암에 비해 성공률이 제한적이지만, 인기를 끌고 있습니다. 전립선 특이적 막 항원(PSMA)을 발현하는 세포에 표적 방사선을 조사하는 루테튬177-PSMA-617과 같은 방사성 리간드 요법의 사용도 큰 진전입니다. 또한 올라파립(olaparib)과 같은 PARP 억제제는 특정 유전자 변이를 가진 환자들에게 효과를 보여 개인 맞춤형 치료의 새로운 길을 제공합니다. 이러한 혁신적인 치료법은 생존율을 향상시킬 뿐만 아니라 기존 치료의 부작용을 줄여 환자의 삶의 질을 향상시키고 있습니다.

전립선암 치료제의 미래를 이끌 혁신이란?

전립선암 치료제의 미래는 몇 가지 중요한 혁신과 연구 진전에 의해 형성되고 있습니다. 개인과 종양의 유전자 프로파일에 따라 치료를 조정하는 정밀의료가 점점 더 중요해지고 있습니다. 유전자 및 분자 프로파일링의 발전으로 특정 치료에 대한 반응을 예측할 수 있는 특정 바이오마커를 식별할 수 있게 되어 보다 효과적이고 맞춤 치료 계획을 수립할 수 있게 되었습니다. 또한 인공지능과 머신러닝이 임상에 통합되면서 방대한 데이터를 분석할 수 있는 능력이 강화되어 의사결정 과정을 개선하고 있습니다. 또 다른 큰 흐름은 고밀도집속초음파(HIFU), 냉동요법 등 부작용이 적고 효과적인 암 제어를 제공하는 최소침습적 치료법의 개발입니다. 이러한 기술 혁신은 치료 결과를 개선할 뿐만 아니라, 환자별 접근과 장기적인 질병 관리를 우선시하는 새로운 치료 패러다임의 길을 열어가고 있습니다.

전립선암 치료제 시장의 성장을 가속하는 요인은 무엇인가?

전립선암 치료제 시장의 성장은 여러 요인에 의해 주도되고 있습니다. 특히 고령화 사회에서 전립선암 발병률 증가는 효과적인 치료법 개발의 필요성이 대두되면서 전립선암 치료제 시장의 성장에 큰 원동력이 되고 있습니다. 진단 및 치료 방법의 기술 발전은 조기 발견과 보다 정확한 치료 옵션을 가능하게 함으로써 시장 성장을 가속하고 있습니다. 맞춤형 의료의 부상과 특정 유전적 및 분자적 표적의 식별으로 치료 수단이 확대되고 치료 결과가 개선되고 있습니다. 또한 공공 및 민간 부문의 암 연구 및 개발에 대한 자금 지원이 증가하면서 혁신적인 치료법의 도입이 가속화되고 있습니다. 전립선암에 대한 인식과 검진에 대한 인식이 높아지면서 진단율이 높아졌고, 이에 따라 치료 수요도 증가하고 있습니다. 이러한 요인들이 복합적으로 작용하여 시장 환경이 역동적으로 확대되고 있으며, 환자 예후를 개선하고 암 치료를 발전시키는 데 중요한 역할을 하고 있습니다.

부문

치료 유형(호르몬 요법, 표적 요법, 화학요법, 표적 요법), 유통 채널(병원 약국, 소매 약국, 온라인 판매, 기타 유통 채널)

조사 대상 기업의 예(주목 76사)

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biotech Inc.
  • Novartis AG
  • Pfizer Inc.
  • Progenics Pharmaceuticals Inc.
  • Sanofi S.A.
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • TOLMAR Pharmaceuticals Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.03.04

Global Prostate Cancer Therapeutics Market to Reach US$26.4 Billion by 2030

The global market for Prostate Cancer Therapeutics estimated at US$18.0 Billion in the year 2024, is expected to reach US$26.4 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$21.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.0 Billion While China is Forecast to Grow at 6.0% CAGR

The Prostate Cancer Therapeutics market in the U.S. is estimated at US$5.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Prostate Cancer Therapeutics Market - Key Trends and Drivers Summarized

What Are the Current Therapeutic Approaches for Prostate Cancer?

Prostate cancer therapeutics encompass a wide range of treatments designed to manage and treat prostate cancer, which is one of the most common cancers among men worldwide. The primary therapeutic approaches include surgery, radiation therapy, hormone therapy, chemotherapy, and more recently, immunotherapy and targeted therapies. Surgical options, such as radical prostatectomy, involve the removal of the prostate gland and are typically recommended for localized cancers. Radiation therapy, delivered either externally or through brachytherapy, targets cancer cells with high-energy rays. Hormone therapy, or androgen deprivation therapy (ADT), reduces the levels of male hormones that fuel prostate cancer growth. Chemotherapy, although less commonly used in early stages, is employed for advanced or hormone-refractory prostate cancers. These treatments are often used in combination to maximize effectiveness and manage the disease more comprehensively.

How Are Emerging Therapies Changing the Landscape of Prostate Cancer Treatment?

Emerging therapies are revolutionizing the treatment landscape for prostate cancer by offering more targeted and personalized treatment options. One of the most promising areas is the development of novel androgen receptor inhibitors, such as enzalutamide and apalutamide, which are more effective in blocking the signals that promote cancer growth. Immunotherapy, particularly the use of immune checkpoint inhibitors, is also gaining traction, although its success in prostate cancer has been more limited compared to other cancers. Another significant advancement is the use of radioligand therapy, such as lutetium-177-PSMA-617, which delivers targeted radiation to prostate-specific membrane antigen (PSMA)-expressing cells. Additionally, PARP inhibitors, like olaparib, have shown efficacy in patients with specific genetic mutations, providing a new avenue for personalized treatment. These innovative therapies are not only improving survival rates but also enhanciwng the quality of life for patients by reducing the side effects associated with traditional treatments.

What Innovations Are Driving the Future of Prostate Cancer Therapeutics?

The future of prostate cancer therapeutics is being shaped by several key innovations and research advancements. Precision medicine, which involves tailoring treatment based on the genetic profile of the individual and their tumor, is becoming increasingly important. Advances in genetic and molecular profiling are enabling the identification of specific biomarkers that can predict response to certain therapies, leading to more effective and individualized treatment plans. Additionally, the integration of artificial intelligence and machine learning in clinical practice is enhancing the ability to analyze vast amounts of data and improve decision-making processes. Another significant trend is the development of minimally invasive treatments, such as high-intensity focused ultrasound (HIFU) and cryotherapy, which offer effective cancer control with fewer side effects. These innovations are not only enhancing therapeutic outcomes but also paving the way for new treatment paradigms that prioritize patient-specific approaches and long-term disease management.

What Factors Are Driving the Growth in the Prostate Cancer Therapeutics Market?

The growth in the prostate cancer therapeutics market is driven by several factors. The increasing incidence of prostate cancer, particularly among aging populations, is a major driver, necessitating the development of effective treatments. Technological advancements in diagnostic and treatment modalities are also propelling market growth, as they enable earlier detection and more precise treatment options. The rise of personalized medicine and the identification of specific genetic and molecular targets are expanding the therapeutic arsenal and improving treatment outcomes. Additionally, increased funding for cancer research and development from both public and private sectors is accelerating the introduction of innovative therapies. The growing awareness and screening initiatives for prostate cancer are leading to higher diagnosis rates and subsequent treatment demand. These factors collectively underscore the dynamic and expanding landscape of the prostate cancer therapeutics market, highlighting its critical role in improving patient outcomes and advancing cancer care.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Hormone Therapy, Targeted Therapy, Chemotherapy, Targeted Therapy); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online sales, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 76 Featured) -

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biotech Inc.
  • Novartis AG
  • Pfizer Inc.
  • Progenics Pharmaceuticals Inc.
  • Sanofi S.A.
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • TOLMAR Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Prostate Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Precision Medicine Propel Growth in Prostate Cancer Therapeutics
    • Increasing Prevalence of Prostate Cancer Spurs Demand for Advanced Treatments
    • Breakthroughs in Immunotherapy Strengthen Business Case for Prostate Cancer Therapeutics
    • Growing Awareness and Screening Programs Accelerate Demand for Early Treatment Options
    • Hormone Therapy Developments Expand Addressable Market Opportunity
    • Innovations in Radiopharmaceuticals Propel Growth in Prostate Cancer Management
    • Regulatory Approvals of Novel Drugs Drive Adoption of Advanced Prostate Cancer Treatments
    • Increasing Investment in Oncology Research Strengthens Prostate Cancer Therapeutics Market
    • Biopharmaceutical Collaborations and Partnerships Spur Innovation in Prostate Cancer Treatments
    • Aging Population Sustains Growth in Prostate Cancer Therapeutics Market
    • Expanding Use of Combination Therapies Generates Opportunities in Prostate Cancer Treatment
    • Growing Pipeline of Prostate Cancer Drugs Strengthens Market Competitiveness
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prostate Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prostate Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Prostate Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Online Sales by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Prostate Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제